Retinopathy of Prematurity - Pathophysiologic Mechanisms and New Treatment Options

被引：0
|
作者：
Stahl, A. [1 ]
Aisenbrey, S. [2 ]
Krohne, T. U. [3 ]
机构：
[1] Univ Freiburg, Univ Augenklin, D-79106 Freiburg, Germany
[2] Univ Tubingen, Univ Augenklin, Tubingen, Germany
[3] Univ Bonn, Univ Augenklin, Bonn, Germany
来源：
KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE | 2012年 / 229卷 / 10期
关键词：
retina; retinopathy of prematurity; ROP; ENDOTHELIAL GROWTH-FACTOR; DIODE-LASER TREATMENT; LONGITUDINAL POSTNATAL WEIGHT; PROLIFERATIVE RETINOPATHY; RETINAL NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB; VEGF; PREDICTOR; INFANTS; GAIN;
D O I：
10.1055/s-0032-1315247
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Retinopathy of prematurity (ROP), like other angioproliferative retinal disorders, has witnessed the advent of anti-VEGF therapy in clinical practice. The first report from the BEAT-ROP study published in 2011 represents the first comparison of anti-VEGF therapy versus conventional laser treatment in a randomised controlled trial. This review article investigates these novel aspects of ROP therapy from a pathophysiological angle and delineates the stages of ROP in which anti-VEGF treatment appears as a reasonable option. Furthermore, the novel chances of anti-VEGF therapy are being weighed against some still unanswered questions and novel study concepts are being presented.
引用
收藏
页码：1024 / 1029
页数：6
相关论文
共 50 条
  • [41] Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment
    Natarajan, Girija
    Shankaran, Seetha
    Nolen, Tracy L.
    Sridhar, Amaanti
    Kennedy, Kathleen A.
    Hintz, Susan R.
    Phelps, Dale L.
    DeMauro, Sara B.
    Carlo, Waldemar A.
    Gantz, Marie G.
    Das, Abhik
    Greenberg, Rachel G.
    Younge, Noelle E.
    Bliss, Joseph M.
    Seabrook, Ruth
    Sanchez, Pablo J.
    Wyckoff, Myra H.
    Bell, Edward F.
    Vohr, Betty R.
    Higgins, Rosemary D.
    PEDIATRICS, 2019, 144 (02)
  • [42] Treatment of retinopathy of prematurity (ROP) outside International Classification of ROP (ICROP) guidelines
    Rajan, Renu P.
    Kohli, Piyush
    Babu, Naresh
    Dakshayini, C.
    Tandon, Manish
    Ramasamy, Kim
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2020, 258 (06) : 1205 - 1210
  • [43] Neurodevelopmental Outcomes after Bevacizumab Treatment for Retinopathy of Prematurity A Meta-analysis
    Tsai, Chia-Ying
    Yeh, Po-Ting
    Tsao, Po-Nien
    Chung, Yu-Chu Ella
    Chang, Yu-Shan
    Lai, Tso-Ting
    OPHTHALMOLOGY, 2021, 128 (06) : 877 - 888
  • [44] Concurrent Physiological and Pathological Angiogenesis in Retinopathy of Prematurity and Emerging Therapies
    Dai, Chang
    Webster, Keith A.
    Bhatt, Amit
    Tian, Hong
    Su, Guanfang
    Li, Wei
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (09)
  • [45] A Paradigm Shift in the Prevention of Retinopathy of Prematurity
    Raghuveer, Talkad S.
    Bloom, Barry T.
    NEONATOLOGY, 2011, 100 (02) : 116 - 129
  • [46] VEGF Antibodies as Therapy for Retinopathy of Prematurity
    Oberacher-Velten, I. M.
    Helbig, H.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2010, 227 (09) : 694 - 700
  • [47] Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity
    Sahin, A.
    Gursel-Ozkurt, Z.
    Sahin, M.
    Turkcu, F. M.
    Yildirim, A.
    Yuksel, H.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2018, 187 (02) : 417 - 421
  • [48] Treatment of retinopathy of prematurity
    Clark, David
    Mandal, K.
    EARLY HUMAN DEVELOPMENT, 2008, 84 (02) : 95 - 99
  • [49] The Determinative Role of Cytokines in Retinopathy of Prematurity
    Rasoulinejad, Seyed Ahmad
    Kiyamehr, Pegah
    CURRENT MOLECULAR MEDICINE, 2023, 23 (01) : 36 - 43
  • [50] The progress of prophylactic treatment in retinopathy of prematurity
    Hong-Bing Zhang
    Xiao-Dong Wang
    Kun Xu
    Xiao-Gang Li
    International Journal of Ophthalmology, 2018, 11 (05) : 858 - 873
12345